2026-04-14T02:49:37Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1259122025-11-20T15:58:37Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Wilson, Wyndham H. author Bromberg, Jacoline E.C. author Stetler-Stevenson, Maryalice author Steinberg, Seth M. author Martin Martin, Lourdes author Muñiz, Carmen author Sancho, Juan Manuel author Caballero García, María Dolores author Davidis, Marjan A. author Brooimans, Rik A. author Sánchez González, Blanca author Salar, Antonio author González Barca, Eva author Ribera, Josep Maria author Shovlin, Margaret author Filie, Armando author Dunleavy, Kieron author Mehrling, Thomas author Spina, Michele author Orfao, Alberto author 2018-11-08T14:26:48Z 2018-11-08T14:26:48Z 2014-07 2018-11-08T14:26:48Z The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk of central nervous system disease is controversial. Furthermore, the effect of intrathecal treatment and rituximab in diffuse large B-cell and Burkitt lymphoma with occult leptomeningeal disease detected by flow cytometry at diagnosis is unknown. Untreated diffuse large B-cell (n=246) and Burkitt (n=80) lymphoma at clinical risk of central nervous system disease and having had pre-treatment cerebrospinal fluid were analyzed by flow cytometry and cytology. Spinal fluid involvement was detected by flow cytometry alone (occult) in 33 (13%) diffuse large B-cell and 9 (11%) Burkitt lymphoma patients, and detected by cytology in 11 (4.5%) and 5 (6%) patients, respectively. Diffuse large B-cell lymphoma with occult spinal fluid involvement had poorer survival (P=0.0001) and freedom from central nervous system relapse (P<0.0001) compared to negative cases. Burkitt lymphoma with occult spinal fluid involvement had an inferior freedom from central nervous system relapse (P=0.026) but not survival. The amount of intrathecal chemotherapy was quantitatively associated with survival in diffuse large B-cell lymphoma with (P=0.02) and without (P=0.001) occult spinal fluid involvement. However, progression of systemic disease and not control of central nervous system disease was the principal cause of treatment failure. In diffuse large B-cell lymphoma, systemic rituximab was associated with improved freedom from central nervous system relapse (P=0.003) but not with survival. Our results suggest that patients at risk of central nervous system disease should be evaluated by flow cytometry and that intrathecal prophylaxis/therapy is beneficial. Limfomes Citometria de fluxe Lymphomas Flow cytometry Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma